Abstract
The rapid developments in the field of genomics and proteomics are expected to lead to a further increase in the potential for early diagnosis, the fine-tuning of prognostic features of specific tumors and the detection of cancer predisposition. Oncogenomics has identified new drug targets for genotype-specific treatments and provided strategies to validate these targets and to develop drugs. With the potential need to stratify patients by genotype, clinical testing of targeted drugs has become more complicated while expectations of patients, investors, and funding agencies have become accelerated. Oncogenomics has progressed logically from molecular profiling to model systems, cancer pharmacology and clinical trials. Oncogenomics covers cutting-edge issues such as array-based diagnostics, pharmacogenomics, pharmacoproteomics and molecularly targeted therapeutics includes discussions of ethical, legal, and social issues related to cancer genomics and clinical trials.
Current Drug Metabolism
Title: Oncogenomics
Volume: 9 Issue: 3
Author(s): Virendra S. Gomase, Somnath Tagore, Karbhari V. Kale and Dayanand A. Bhiwgade
Affiliation:
Abstract: The rapid developments in the field of genomics and proteomics are expected to lead to a further increase in the potential for early diagnosis, the fine-tuning of prognostic features of specific tumors and the detection of cancer predisposition. Oncogenomics has identified new drug targets for genotype-specific treatments and provided strategies to validate these targets and to develop drugs. With the potential need to stratify patients by genotype, clinical testing of targeted drugs has become more complicated while expectations of patients, investors, and funding agencies have become accelerated. Oncogenomics has progressed logically from molecular profiling to model systems, cancer pharmacology and clinical trials. Oncogenomics covers cutting-edge issues such as array-based diagnostics, pharmacogenomics, pharmacoproteomics and molecularly targeted therapeutics includes discussions of ethical, legal, and social issues related to cancer genomics and clinical trials.
Export Options
About this article
Cite this article as:
Gomase S. Virendra, Tagore Somnath, Kale V. Karbhari and Bhiwgade A. Dayanand, Oncogenomics, Current Drug Metabolism 2008; 9(3) . https://dx.doi.org/10.2174/138920008783884713
DOI https://dx.doi.org/10.2174/138920008783884713 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Anti-diabetic Drug Metformin: Challenges and Perspectives for Cancer Therapy
Current Cancer Drug Targets Development of Small-Molecule Inhibitors of Raf
Recent Patents on Anti-Infective Drug Discovery Na+-H+ Exchanger, pH Regulation and Cancer
Recent Patents on Anti-Cancer Drug Discovery Myeloid Derived Suppressor Cells and Their Role in Diseases
Current Medicinal Chemistry Future Targets in Endothelial Biology: Endothelial Cell to Mesenchymal Transition
Current Drug Targets Development of FXR, PXR and CAR Agonists and Antagonists for Treatment of Liver Disorders
Current Topics in Medicinal Chemistry Morphological and Molecular Changes of the Myocardium After Left Ventricular Mechanical Support
Current Cardiology Reviews Resveratrol Targets in Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Peptidic Tumor Targeting Agents: The Road from Phage Display Peptide Selections to Clinical Applications
Current Pharmaceutical Design DNMT Inhibitors in Cancer, Current Treatments and Future Promising Approach: Inhibition of Specific DNMT-Including Complexes
Epigenetic Diagnosis & Therapy (Discontinued) Biomarker Diversity, Validation and Clinical Translation: Tenets for Emergent Personalized Medicine Initiatives
Current Pharmacogenomics and Personalized Medicine Mechanisms of Intrinsic and Acquired Resistance to EGFR Inhibitors
Current Cancer Therapy Reviews Noscapine and its Analogs as Chemotherapeutic Agent: Current updates
Current Topics in Medicinal Chemistry Valproic Acid As Anti-Cancer Drug
Current Pharmaceutical Design Functional Nanoplatforms for Enhancement of Chemotherapeutic Index
Anti-Cancer Agents in Medicinal Chemistry Molecular Targeting of Protein Kinases to Optimize Selectivity and Resistance Profiles of Kinase Inhibitors
Current Topics in Medicinal Chemistry Inhibiting Glutathione Metabolism in Lung Lining Fluid as a Strategy to Augment Antioxidant Defense
Current Enzyme Inhibition Inhibitors of the Immunoproteasome: Current Status and Future Directions
Current Pharmaceutical Design Deregulation of the Akt Pathway in Human Cancer
Current Cancer Drug Targets Metabolomics of Serum Peptides
Protein & Peptide Letters